Funding and Investments

Lilly Plans to Grow its Biologics Manufacturing Footprint in Ireland with $1.8 Billion Expansion

September 18, 2024

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

US Specialty Formulations Conducts $15 Million Expansion on Biopharma Operations

August 08, 2024

With a $15 million fund-raising goal, US Specialty Formulations plans to invest in expanding its biopharma facility in Allentown, Pa.

Biotech Company, Third Arc Bio, Receives $165 Million in Financing to Advance Biologic Drug Development Pipeline

July 31, 2024

The new biotech company will use the Series A financing to advance the development of enhanced biologics to treat solid tumors and inflammatory and immunology diseases.

BeiGene Launches Biologics Manufacturing and Clinical R&D Facility in New Jersey

July 25, 2024

BeiGene has invested $800 million into a new biologics manufacturing facility in Hopewell, NJ, which also houses its clinical R&D capabilities.

Novo Nordisk Targets $4.1 Billion Expansion of US Manufacturing Capacity

June 26, 2024

Novo Nordisk plans to invest $4.1 billion in a second fill/finish manufacturing facility in Clayton, N.C., boosting its current 2024 investments into production to $6.8 billion.

AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

June 11, 2024

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.

Increased Capacity Needed for Mammalian Cell Culture (BIO 2024)

June 07, 2024

FUJIFILM Diosynth Biotechnologies CEO Lars Petersen highlights the company’s strategic goals and meeting market demand for mammalian cell culture capacity.

AstraZeneca Invests $1.5 Billion to Build New ADC Manufacturing Facility in Singapore

May 21, 2024

This new facility will allow AstraZeneca to offer full manufacturing processing for antibody drug conjugates.

Lonza Acquires Roche’s US Commercial Biologics Manufacturing Site for $1.2 Billion

March 25, 2024

With the Vacaville, Calif., site acquisition, Lonza gains one of the largest biologics manufacturing sites for mammalian cell-based therapeutics.

Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs

February 22, 2024

Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.